pazopanib + bevacizumab + everolimus

A multi-agent oncology regimen combining the small-molecule VEGF/PDGF receptor tyrosine kinase inhibitor pazopanib, the anti-VEGF monoclonal antibody bevacizumab, and the mTOR inhibitor everolimus. The rationale is dual blockade of VEGF signaling (ligand sequestration by bevacizumab plus receptor tyrosine kinase inhibition by pazopanib) together with inhibition of the PI3K/AKT/mTOR pathway via everolimus to reduce angiogenesis, tumor growth, and resistance mechanisms in metastatic renal cell carcinoma and other solid tumors. Combination regimens pairing VEGF pathway inhibitors with mTOR inhibitors have shown increased toxicity and mixed efficacy; bevacizumab with everolimus has demonstrated activity in RCC, while pazopanib with bevacizumab has shown significant toxicity requiring dose reductions in early studies. This specific triple combination has been conceptually supported by these mechanisms but lacks established clinical evidence as a unified three-drug regimen.

Other names

pazopanib plus bevacizumab plus everolimus